If you have been reading about somatotroph and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-03-03. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
== Background == The value of urine for diagnostic purposes has been recognized since ancient times. Urine examination was practiced in Sumer and Babylonia as early as 4000 BC, and is described in ancient Greek and Sanskrit texts. Contemporary urine testing uses a range of methods to investigate the physical and biochemical properties of the urine. For instance, the results of the routine urinalysis can provide information about the functioning of the kidneys and urinary system; suggest the presence of a urinary tract infection (UTI); and screen for possible diabetes or liver disease, among other conditions. A urine culture can be performed to identify the bacterial species involved in a UTI. Simple point-of-care tests can detect pregnancy by identifying the presence of beta-hCG in the urine and indicate the use of recreational drugs by detecting excreted drugs or their metabolites. Analysis of abnormal cells in urine (urine cytology) can help to diagnose some cancers, and testing for organic acids or amino acids in urine can be used to screen for some genetic disorders.
Lance Armstrong doping case (2012) – after having been accused of doping for much of the latter part of his career, Lance Armstrong became the subject of an investigation by the United States Anti-Doping Agency. The USADA report revealed that he had engaged in a highly sophisticated doping campaign from 1998 onward. Following the report, the UCI stripped all of Armstrong's results and awards from that time forward, including his then-record seven Tour de France wins. Biogenesis baseball scandal (2013) – more than a dozen MLB players were found to have received PEDs, mainly human growth hormone, from a now-defunct anti-aging clinic in the Miami area. In all, 13 players received suspensions of 50 or more games, with the longest being given to Alex Rodriguez (162 games) and Ryan Braun (65 games). The number of players suspended is the most for any single incident in the history of organized baseball in North America. Essendon Football Club supplements saga (2013) – in February 2013, the Essendon Football Club, a professional Australian rules football club participating in the Australian Football League (AFL), were investigated by the Australian Sports Anti-Doping Authority (ASADA) and the World Anti-Doping Agency (WADA) over the legality of its supplements program during the 2012 AFL season and the preceding preseason. In January 2016, the players were found guilty of having used the banned peptide thymosin beta-4, resulting in the suspensions of thirty-four players who were part of the program.
As an ointment, tacrolimus is used in the treatment of dermatitis (eczema), in particular atopic dermatitis, if topical corticosteroids and moisturisers fail in helping. It suppresses inflammation in a similar way to steroids, and is equally as effective as a mid-potency steroid. An important advantage of tacrolimus is that, unlike steroids, it does not cause skin thinning (atrophy), or other steroid related side effects. It is applied on the active lesions until they heal off, but may also be used continuously in low doses (twice a week), and applied to the thinner skin over the face and eyelids. Clinical trials of up to one year have been conducted. Recently it has also been used to treat segmental vitiligo in children, especially in areas on the face.
=== 1982 === February 24: President Ronald Reagan announces the "Caribbean Basin Initiative" to prevent the overthrow of governments in the region by the forces of communism. March 22: President Ronald Reagan signs P.L. 97-157 denouncing the government of the Soviet Union that it should cease its abuses of the basic human rights of its citizens. April 2: Argentina invades the Falkland Islands, starting the Falklands War. May 30: Spain joins NATO. June 6: Israel invades Lebanon to end raids and clashes with Syrian troops based there. June 14: Falkland Islands liberated by British task force. End of the Falklands War. August 1: Rebels attempt to seize control of Kenya, with the supposed assist of the communists in a coup d'état. The coup failed. November 10: Leonid Brezhnev dies from a heart failure with his funeral being held five days later. November 14: Yuri Andropov becomes General Secretary of the Soviet Union.
It has local production plants in Bologna and Florence in Italy along with other manufacturing sites in Germany, France, Switzerland, Spain, United Kingdom, U.S.A., India, Malaysia and China. More than 5,000 are employed in the company, 2,600 of those work abroad. Its annual turnover in 2016 was €1.310,55 million. Its employees number more than 5,000 (with about 2,600 outside of Italy) in 41 manufacturing sites in Italy, Germany, France, Switzerland, Spain, the UK, the US, India, Malaysia, China and Argentina. Its sales network covers more than 80 countries. The Group has around 6,000 employees, of which over 2,800 overseas, and has 45 production plants in Italy, Germany, France, Switzerland, Spain, United Kingdom, United States, India, Malaysia, China and Argentina. IMA has an extensive commercial network, which consists of 29 branches with sales and assistance services in Italy, France, Switzerland, United Kingdom, Germany, Austria, Spain, Poland, Israel, Russia, United States, India, China, Malaysia, Thailand and Brazil, representative offices in Central and Eastern European countries and more than 50 agencies covering a total of about 80 countries. In addition, in 2019, it had a turnover of 1,595.5 million euros, of which about 90% outside Italy.
Sources: en.wikipedia.org
Only 10 to 15% of tumours are suitable for surgical resection. As of 2018, when chemotherapy is given the FOLFIRINOX regimen containing fluorouracil, irinotecan, oxaliplatin and leucovorin has been shown to extend survival beyond traditional gemcitabine regimens. For the most part, treatment is palliative, focusing on the management of symptoms that develop. This may include management of itch, a choledochojejunostomy, or the insertion of stents with ERCP to facilitate the drainage of bile, and medications to help control pain. In the United States, pancreatic cancer is the fourth most common cause of death due to cancer. The disease occurs more often in the developed world, which had 68% of new cases in 2012. Pancreatic adenocarcinoma typically has poor outcomes, with the average percentage alive for at least one and five years after diagnosis being 25% and 5% respectively. In localized disease where the cancer is small (< 2 cm) the number alive at five years is approximately 20%. There are several types of pancreatic cancer, involving both the endocrine and exocrine tissue. The many types of pancreatic endocrine tumors are all uncommon or rare, and have varied outlooks. However, the incidence of these cancers has been rising sharply; it is not clear to what extent this reflects increased detection, especially through medical imaging, of tumors that would be very slow to develop. Insulinomas (largely benign) and gastrinomas are the most common types.
A small portion of approximately 3% of testosterone is reversibly converted in the liver into androstenedione by 17β-HSD. In addition to conjugation and the 17-ketosteroid pathway, testosterone can also be hydroxylated and oxidized in the liver by cytochrome P450 enzymes, including CYP3A4, CYP3A5, CYP2C9, CYP2C19, and CYP2D6. 6β-Hydroxylation and to a lesser extent 16β-hydroxylation are the major transformations. The 6β-hydroxylation of testosterone is catalyzed mainly by CYP3A4 and to a lesser extent CYP3A5 and is responsible for 75 to 80% of cytochrome P450-mediated testosterone metabolism. In addition to 6β- and 16β-hydroxytestosterone, 1β-, 2α/β-, 11β-, and 15β-hydroxytestosterone are also formed as minor metabolites. Certain cytochrome P450 enzymes such as CYP2C9 and CYP2C19 can also oxidize testosterone at the C17 position to form androstenedione. Two of the immediate metabolites of testosterone, 5α-DHT and estradiol, are biologically important and can be formed both in the liver and in extrahepatic tissues. Approximately 5 to 7% of testosterone is converted by 5α-reductase into 5α-DHT, with circulating levels of 5α-DHT about 10% of those of testosterone, and approximately 0.3% of testosterone is converted into estradiol by aromatase. 5α-Reductase is highly expressed in the male reproductive organs (including the prostate gland, seminal vesicles, and epididymides), skin, hair follicles, and brain and aromatase is highly expressed in adipose tissue, bone, and the brain.
The Ministry also indicated it had captured 4 of the Comandos de la Frontera, who were later released. The United States Department of Defense, did not comment as an investigation into the event is ongoing, but referred the matter to the Office of the Director of National Intelligence for further questions. In January 2026, an Ecuadorian fishing vessel, carrying eight crew members disappeared, while two other crew member were away. When they returned to the boat's last know location, there was no sign of it and it is unknown what happened to it. In March, two Ecuadorian fishing vessels near the Galápagos Islands in Ecuador's exclusive economic zone were attacked and damaged by small, explosive-laden rotor drones. In both these incidents, the crews reported being later taken aboard a U.S. military vessel and later transferred to El Salvador and handed over to the authorities there, before being returned to Ecuador. The Washington Post reported in August that the two Galápagos boat strikes were part of a covert CIA program, although CNN said they could not independently verify this. While the US has admitted attacking dozens of alleged drug-trafficking vessels in the Caribbean and Pacific, they have denied responsibility for these incidents. Ecuadorian authorities have also largely not commented on them. In late August, the U.S., in collaboration with Ecuador, began sinking Ecuadorian vessels alleged to be involved drug traffickiing. Within two weeks, six vessels were sunk, with the crews being removed and transferred to Ecuadorian authorities before the boats were sunk.
== Function == CGRP is produced in both peripheral and central neurons. It is a potent peptide vasodilator and can function in the transmission of nociception. In the spinal cord, the function and expression of CGRP may differ depending on the location of synthesis. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and may contribute to the regeneration of nervous tissue after injury. Conversely, CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and may be linked to the transmission of pain. In the trigeminal vascular system, the cell bodies of the trigeminal ganglion are the main source of CGRP. CGRP is thought to play a role in cardiovascular homeostasis and nociception. In the heart, CGRP acts as a chronotrope by increasing heart rate. Apart from these attributes, CGRP is known to modulate the autonomic nervous system and plays a role in ingestion. CGRP has moderate effects on calcium homeostasis compared to its extensive actions in other areas, such as the autonomic nervous system.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.